Clareo Health | A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
5–45
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Males and females
Availability of a parent or other reliable caregiver. The same person must agree to accompany the participant to all clinic visits and provide information about the participant's behavior and symptoms
Age: 5-45 years
Diagnosis of ASD based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), and the Autism Diagnostic Observation Schedule (ADOS-2).
Children's Yale-Brown Obsessive Compulsive Scale modified for ASD (CY-BOCS-ASD) total score of at least 12
Clinical Global Impression-Severity (CGI-S) scale of at least 4 about participant's current autism severity
Intelligence quotient (IQ) score of 50 or above as assessed by the Abbreviated Intelligence Quotient (ABIQ) SB5 scale
All medications and treatments are expected to be stable for the duration of the study
TD participants aged 5-45 years
You may not be if
Participation in an in investigational drug or device study within 4 weeks or 5 times the half-life of the investigational molecule prior to screening, and participant is not expected to enroll in any other trial during the study
Co-occurring disease, condition, or treatment that might interfere with the conduct of the study or pose an unacceptable risk to the participant
Unstable or uncontrolled clinically significant psychiatric and/or neurological disorder that may interfere with study objectives
TD healthy participants with a first-degree relative with ASD
